Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.0K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.0K
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

555
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
555
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.3K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.4K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Knockout of PAK1 and PAK4 supresses tumour growth associated with vasculogenic mimicry inhibition through EphA2-VE-cadherin-MCAM pathway.

Cell communication and signaling : CCS·2026
Same author

A Streamlined Protocol for Developing a Clinicopathological Prediction Model for Patient Survival of Post-Resection of Pancreatic Cancer.

Cancer medicine·2026
Same author

Evaluation of Nanoparticle-Based Plasma Enrichment on Individuals with Primary and Metastatic Pancreatic Cancer.

Cancers·2025
Same author

Targeting PAK1 or PAK4 Uncovers Different Mechanisms of Vascular Reprogramming in Pancreatic Cancer.

Cells·2025
Same author

The Effects of PAK-Regulated Tumour Vasculature on Gemcitabine Response of Pancreatic Cancer.

Cancers·2025
Same author

P-21 Kinase 1 or 4 Knockout Stimulated Anti-Tumour Immunity Against Pancreatic Cancer by Enhancing Vascular Normalisation.

International journal of molecular sciences·2025

Related Experiment Video

Updated: Dec 3, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

Cannabinoids Inhibited Pancreatic Cancer via P-21 Activated Kinase 1 Mediated Pathway.

Yang Yang1,2, Nhi Huynh1,3, Chelsea Dumesny1

  • 1Department of Surgery, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia.

International Journal of Molecular Sciences
|October 31, 2020
PubMed
Summary

Cannabidiol (CBD) and Tetrahydrocannabinol (THC) show anti-cancer effects in pancreatic cancer by inhibiting tumor growth and PD-L1 expression. These cannabinoids target the PAK1 pathway, offering potential for immune checkpoint blockade enhancement.

Keywords:
CBDPAK1PD-L1PDATHC

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.2K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.5K

Related Experiment Videos

Last Updated: Dec 3, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.2K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Pancreatic cancer (PC) is characterized by frequent KRas mutations.
  • Cannabinoids like CBD and THC have demonstrated anti-cancer properties.
  • The specific mechanisms of CBD and THC in PC, particularly concerning KRas and PD-L1, require further investigation.

Purpose of the Study:

  • To investigate the anti-cancer effects of CBD and THC on pancreatic cancer cells and their interaction with pancreatic stellate cells (PSCs).
  • To elucidate the role of the KRas-activated pathway, specifically PAK1, in mediating the effects of CBD and THC.
  • To determine the impact of CBD and THC on PD-L1 expression in pancreatic cancer.

Main Methods:

  • Utilized pancreatic cancer cell lines and mouse models for in vitro and in vivo studies.
  • Performed cell-based assays to assess proliferation and interaction between PC cells and PSCs.
  • Analyzed the expression of PD-L1 and the role of p-21 activated kinase 1 (PAK1) through gene knockout studies.

Main Results:

  • CBD and THC inhibited the proliferation of pancreatic cancer cells, pancreatic stellate cells, and PSC-stimulated PC cells.
  • CBD and THC suppressed pancreatic tumor growth in vivo.
  • CBD and THC reduced PD-L1 expression in both PC and PSC cells.
  • Knockout of PAK1 significantly diminished or abolished the inhibitory effects of CBD and THC.

Conclusions:

  • CBD and THC exert their anti-cancer effects in pancreatic cancer and PSCs through a PAK1-dependent pathway.
  • These cannabinoids appear to suppress the KRas-activated pathway by targeting PAK1.
  • The observed reduction in PD-L1 expression by CBD and THC suggests a potential to enhance immune checkpoint blockade therapy for pancreatic cancer.